Celldex Therapeutics, Inc. (CLDX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Anthony S. Marucci M.B.A.
|
Founder, President, CEO & Director | 1.34M | -- | 1962 |
|
Dr. Tibor Keler Ph.D.
|
Founder, Chief Scientific Officer & Executive VP | 867.16k | -- | 1959 |
|
Mr. Sam Martin CPA
|
Senior VP, CFO, Secretary & Treasurer | 739.66k | -- | 1971 |
|
Ms. Elizabeth Crowley
|
Chief Product Development Officer & Senior VP | 744.06k | -- | 1972 |
|
Dr. Margo Heath-Chiozzi M.D.
|
Senior Vice President of Regulatory Affairs | 719.48k | -- | 1957 |
|
Prof. Joseph P. Schlessinger Ph.D.
|
Co-Founder & Member of Scientific Advisory Board | -- | -- | 1945 |
|
Ms. Sarah Cavanaugh
|
Senior Vice President of Corporate Affairs & Administration | -- | -- | 1975 |
|
Mr. Freddy A. Jimenez Esq.
|
Senior VP & General Counsel | 579.7k | -- | 1969 |
|
Dr. Ronald A. Pepin Ph.D.
|
Chief Business Officer & Senior VP | 441.84k | -- | 1956 |
|
Dr. Diane C. Young M.D.
|
Senior VP & Chief Medical Officer | 696.45k | -- | 1957 |
Celldex Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 198
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Corporate Governance
Upcoming Events
November 9, 2026 at 9:00 PM UTC
Celldex Therapeutics, Inc. Earnings Date
